Rigel Pharmaceuticals, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014. Rigel is a clinical-stage drug developer focused on inflammatory and autoimmune diseases and muscle disorders; it had no commercial product revenue.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 / prior period |
|---|---|---|
| Collaboration revenue | $0 | $0 |
| Research and development expense | $16.9 million | $20.3 million |
| General and administrative expense | $5.5 million | $5.4 million |
| Operating loss | $22.4 million | $25.7 million |
| Net loss | $22.3 million | $25.6 million |
| Basic and diluted loss per share | $0.25 | $0.29 |
| Operating cash used | $16.4 million | $25.1 million |
| Cash, cash equivalents and available-for-sale securities | $195.4 million | $212.0 million at Dec. 31, 2013 |
Loss margins are not meaningful because the company reported no revenue. Cash and investments declined by about $16.6 million from year-end, while cash and cash equivalents alone fell to $14.9 million. Current assets were $197.8 million and current liabilities $7.9 million. The balance sheet lists no borrowings; it reports deferred rent and other liabilities. Facilities lease commitments totaled $58.8 million, including $14.5 million due within one year.
Changes and operating developments
- R&D expense fell $3.4 million year over year, mainly because R343’s asthma Phase 2 trial and R333’s discoid lupus Phase 2 trial had ended, and following a 2013 workforce reduction. Higher fostamatinib ITP spending and stock compensation partly offset the decrease.
- G&A expense increased $0.1 million, mainly due to higher stock-based compensation. Interest income declined to $82,000 from $136,000, reflecting lower average investment balances.
- Net loss improved by $3.3 million year over year. Operating cash use also decreased; investing cash inflow was $10.5 million, principally from net maturities of securities. Financing provided $24,000.
- Rigel reported $2.4 million of stock-based compensation, including performance-based options tied to fostamatinib’s ITP Phase 3 progress. A Purchase Plan reset generated approximately $577,000 of incremental fair value to be recognized over time.
Outlook, risks and contingencies
- Management expected existing capital resources to fund current and projected requirements through Q2 2016, while warning that assumptions could prove wrong. Rigel anticipated higher R&D spending for the remainder of 2014 as clinical programs advanced.
- Planned milestones included starting two pivotal fostamatinib Phase 3 ITP studies in Q2 and Q3 2014, with top-line results expected by year-end 2015; a Phase 2 IgAN study in the second half of 2014; and an R348 dry-eye study in patients with ocular graft-versus-host disease in Q2 2014. R348 dry-eye Phase 2 results were expected in Q3 2014. R118 had entered Phase 1 for intermittent claudication.
- Fostamatinib’s prior rheumatoid arthritis Phase 3 program did not support regulatory filings; AstraZeneca returned the rights, and Rigel discontinued development for RA and lymphoma. Rigel planned to fund ITP development itself and could seek another partner.
- Management said further funding would be needed over time. Equity financing could dilute shareholders; debt could impose restrictive covenants; and licensing or collaboration deals could require surrendering rights. Potential collaboration milestones exceeding $152.3 million are contingent on partner achievements, may never be received, and are not assured funding.
- Key risks include clinical failure or delays, regulatory uncertainty, reliance on third-party manufacturers and collaborators, competition, intellectual-property disputes, and potential need for additional capital. The filing reported no legal proceedings and no material off-balance-sheet arrangements. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether fostamatinib’s planned ITP trials started on schedule and whether results support continued development.
- Whether the stated cash runway through Q2 2016 remains credible as trial spending rises, and how quickly cash and investments are consumed.
- Progress and results for R348 and R118, including whether announced study timelines were met.
- Any new collaboration, financing, milestone payment, or change in the status of partnered programs.
- Whether lease commitments, clinical-trial accrual estimates, and stock-based compensation materially change in subsequent filings.